Inflammatory bowel disease (IBD) is a common diarrheal illness with gastrointestinal and extraintestinal manifestations and complications. The most common infectious complication associated with IBD is Clostridioides difficile infection (CDI). Active IBD predisposes to CDI due to alterations in the gut microbiome. C. difficile is a toxin producing bacterium leading to worsening of underlying IBD, increasing the risk of IBD treatment failure and an increased risk of hospitalization and surgery. Since the symptoms of CDI overlap with those of an IBD flare; it is prudent to recognize that the diagnosis of CDI is challenging and diagnostic tests (nucleic-acid and toxin-based assays) should be interpreted in context of symptoms and test performance. First line treatments for management of CDI in IBD include vancomycin or fidaxomicin. Recurrence prevention strategies should be implemented to mitigate recurrent CDI risk. One needs to monitor IBD disease progression and manage immunosuppression. The risk of recurrent CDI after a primary infection is higher in IBD compared to non-IBD patients. Microbiota restoration therapies are effective to prevent recurrent CDI in IBD patients. This review summarizes the epidemiology, pathophysiology, diagnostic testing, outcomes and management of both CDI and IBD, in CDI complicating IBD.
Citations
Citations to this article as recorded by
Higher disease activity of inflammatory bowel disease predisposes to Clostridioides difficile infection Krista Vitikainen, Merit Kase, Leo Meriranta, Pauliina Molander, Clas-Göran af Björkesten, Veli-Jukka Anttila, Perttu Arkkila Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Discordance in Clinical Indicators With Sequential Fecal Microbiota Transplantation: A Case of Fulminant Clostridioides Difficile Infection Peter Bhandari, Reanay Berezovskiy, Salima Makhani, Valerie Gausman, Neelesh Rastogi, Sabina Braude ACG Case Reports Journal.2025; 12(6): e01731. CrossRef
Phage therapy modulates the gut microbiome and immune responses in non-typhoidal Salmonella-induced colitis Md. Sharifull Islam, Ping Wei, Kaimin Zhang, Ishatur Nime, Fan Pan Food Research International.2025; 219: 117003. CrossRef
Recurrent Clostridium difficile Infections in a Patient With Ulcerative Colitis: A Case Report Osama Nadeem, Muhammad Soban Imran, Nasir Siddique Cureus.2025;[Epub] CrossRef
Patient with Inflammatory Bowel Disease in a Dental Office—Which Antibiotic to Choose?—Narrative Review Stanisław Niemczyk, Wojciech Niemczyk, Katarzyna Bąk-Drabik, Katarzyna Latusek-Kotyczka, Anna Zawilska, Rafał Wiench, Jakub Hadzik, Marzena Dominiak Journal of Clinical Medicine.2025; 14(23): 8392. CrossRef
Enteric opportunistic infections in patients with inflammatory bowel disease receiving biologic therapies: a retrospective cohort study Ting-Chieh Huang, Tony Kou, Chia-Jung Kuo, Cheng-Hsun Chiu, Tai-Di Chen, Chien-Ming Chen, Jen-Wei Chou, Tien-Yu Huang, Chen-Wang Chang, Cheng-Tang Chiu, Ming-Yao Su, Yu-Bin Pan, Puo-Hsien Le Gut Pathogens.2025;[Epub] CrossRef
Special Issue “Bacterial Toxins and Cancer” Sara Travaglione, Francesca Carlini, Zaira Maroccia, Alessia Fabbri International Journal of Molecular Sciences.2024; 25(4): 2128. CrossRef
19-Year-Old Man With Abdominal Pain, Vomiting, Bloody Diarrhea, and Rash David L. Farrier, David Chiang, Amindra S. Arora Mayo Clinic Proceedings.2024; 99(6): 980. CrossRef
Pharmacological effects of ginseng and ginsenosides on intestinal inflammation and the immune system Linxian Zhao, Tongbo Zhang, Kai Zhang Frontiers in Immunology.2024;[Epub] CrossRef
Clostridioides difficile infection in inflammatory bowel disease: a clinical review Mengjun Tang, Chunhua Wang, Ying Xia, Jian Tang, Jiao Wang, Liang Shen Expert Review of Anti-infective Therapy.2024; 22(5): 297. CrossRef
Management of Clostridioides difficile infection: an Italian Delphi consensus Matteo Bassetti, Antonio Cascio, Francesco Giuseppe De Rosa, Marianna Meschiari, Roberto Parrella, Nicola Petrosillo, Alessandro Armuzzi, Flavio Caprioli, Francesco Dentali, Marcello Pani, Alberto Pilotto, Umberto Restelli, Maurizio Sanguinetti Journal of Antimicrobial Chemotherapy.2024; 79(9): 2103. CrossRef
Treatment outcomes of mild to moderate Clostridioides difficile infection in inflammatory bowel disease: an Australian experience Rachael Jacob, Virginia Chu, Watson Ng, Astrid‐Jane Williams, Susan Connor Internal Medicine Journal.2024; 54(12): 2009. CrossRef
Clinical outcomes for Clostridioides difficile associated diarrhea in inflammatory bowel disease patients versus non-IBD population: A retrospective cohort study Genady Drozdinsky, Alaa Atamna, Hagar Banai, Haim Ben-Zvi, Jihad Bishara, Noa Eliakim-Raz Medicine.2023; 102(6): e32812. CrossRef
Clostridioides difficile Toxin B Induced Senescence: A New Pathologic Player for Colorectal Cancer? Katia Fettucciari, Alessandro Fruganti, Fabrizio Stracci, Andrea Spaterna, Pierfrancesco Marconi, Gabrio Bassotti International Journal of Molecular Sciences.2023; 24(9): 8155. CrossRef
Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: A retrospective cohort study from northern India Sandeep Mundhra, David Thomas, Saransh Jain, Pabitra Sahu, Sudheer Vuyyuru, Peeyush Kumar, Bhaskar Kante, Rajesh Panwar, Peush Sahni, Rama Chaudhry, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja Indian Journal of Gastroenterology.2023; 42(3): 411. CrossRef
Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park Frontiers in Medicine.2023;[Epub] CrossRef
Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease Andree H Koop, Paul M Travers, Sahil Khanna, Darrell S Pardi, Francis A Farraye, Jana G Hashash Journal of Gastroenterology and Hepatology.2023; 38(11): 1910. CrossRef
Clostridioides difficile Infection in Inflammatory Bowel Disease Patients: A Systematic Review of Risk Factors and Approach in Management Leslie Sangurima, Maujid Masood Malik, Nency Ganatra, Rosemary Siby, Sanjay Kumar, Sara Khan, Doju Cheriachan, Lubna Mohammed Cureus.2023;[Epub] CrossRef
Role of the Alteration in Calcium Homeostasis in Cell Death Induced by Clostridioides difficile Toxin A and Toxin B Katia Fettucciari, Fabrizio Dini, Pierfrancesco Marconi, Gabrio Bassotti Biology.2023; 12(8): 1117. CrossRef
Gut Microbiota Associated with Clostridioides difficile Carriage in Three Clinical Groups (Inflammatory Bowel Disease, C. difficile Infection and Healthcare Workers) in Hospital Field Elisa Martinez, Sebastien Crevecoeur, Carine Thirion, Jessica Grandjean, Papa Abdoulaye Fall, Marie-Pierre Hayette, Moutschen Michel, Bernard Taminiau, Edouard Louis, Georges Daube Microorganisms.2023; 11(10): 2527. CrossRef
Prevalence of Clostridium Difficile Infection (CDI) among Inflammatory Bowel Disease (IBD) Patients in Comparison to Non-IBD Patients in King Abdulaziz Medical City in Jeddah Ghassan Abdulrahman Sukkar, Syed Sameer Aga, Abdulrahman Hamid Alsamadani, Faisal Ghazi Almalki, Ali Saleh Alsudais, Abdulrahman Sulaiman Alquzi, Mohamed Eldigire Ahmed, Mushtaq Ahmad Mir, Moudi M. Alasmari, Shivendra Singh Interdisciplinary Perspectives on Infectious Diseases.2023; 2023: 1. CrossRef
Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Joon Seop Lee, Sung Kook Kim, Yun Jin Jung, Sang-Bum Kang, Manasi Agrawal, Ryan Ungaro, Jean-Frederic Colombel Digestive Diseases and Sciences.2022; 67(7): 2866. CrossRef
Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis Sheng-Bo Fang, Yan-Qing Song, Chun-Yan Zhang, Li-Bo Wang World Journal of Pediatrics.2022; 18(1): 27. CrossRef
Clostridium innocuum infection in hospitalised patients with inflammatory bowel disease Puo-Hsien Le, Cheng-Tang Chiu, Pai-Jui Yeh, Yu-Bin Pan, Cheng-Hsun Chiu Journal of Infection.2022; 84(3): 337. CrossRef
Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics Quan Lu, Mei-feng Yang, Yu-jie Liang, Jing Xu, Hao-ming Xu, Yu-qiang Nie, Li-sheng Wang, Jun Yao, De-feng Li Journal of Inflammation Research.2022; Volume 15: 1825. CrossRef
Clostridioides Infection in Patients with Inflammatory Bowel Disease Mi Rae Lee, Eun Soo Kim The Korean Journal of Gastroenterology.2022; 80(2): 66. CrossRef
Viral Hepatitis in Patients with Inflammatory Bowel Disease Seung Hwan Shin, Sang Hyoung Park The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef
Exploration of Potential Gut Microbiota-Derived Biomarkers to Predict the Success of Fecal Microbiota Transplantation in Ulcerative Colitis: A Prospective Cohort in Korea Gi-Ung Kang, Sowon Park, Yeongyun Jung, Jai J. Jee, Min-Sueng Kim, Seungjun Lee, Dong-Woo Lee, Jae-Ho Shin, Hong Koh Gut and Liver.2022; 16(5): 775. CrossRef
Do We Have an Opportunity to Avoid Opportunistic Infections in Asian Patients with Inflammatory Bowel Disease? Suhyun Park, Sang Hyoung Park Gut and Liver.2022; 16(5): 663. CrossRef
Using next-generation sequencing to develop a Shigella species threshold and profile faecal samples from suspected diarrhoea cases Ann Smith Folia Microbiologica.2021; 66(3): 399. CrossRef
Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection Sarah Rotondo‐Trivette, Beibei Wang, Christopher Gayer, Riddhi Parsana, Yihui Luan, Fengzhu Sun, Sonia Michail Alimentary Pharmacology & Therapeutics.2021; 54(6): 792. CrossRef
Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease May be Favoured by the Effects of Proinflammatory Cytokines on the Enteroglial Network Gabrio Bassotti, Alessandro Fruganti, Giovanni Maconi, Pierfrancesco Marconi, Katia Fettucciari Journal of Inflammation Research.2021; Volume 14: 7443. CrossRef